Literature DB >> 27278807

Outcome in dogs with advanced (stage 3b) anal sac gland carcinoma treated with surgery or hypofractionated radiation therapy.

V Meier1, G Polton2, S Cancedda3, M Roos4, P Laganga3, T Emmerson2, C Rohrer Bley1.   

Abstract

Stage 3b anal sac gland carcinoma (ASGC) can be life-threatening. A surgical approach is not always possible or may be declined. Dogs with stage 3b ASGC treated with surgery or conformal radiation therapy (RT) with 8 × 3.8 Gy (total dose 30.4 Gy, over 2.5 weeks) were retrospectively evaluated. Patient characteristics, median progression-free interval (PFI) and median survival time (MST) were compared. Twenty-eight dogs were included; 15 underwent surgery, 13 underwent RT. At the time of presentation, 21% showed life-threatening obstipation and 25% showed hypercalcaemia. PFI and MST for surgery cases were 159 days (95% CI: 135-184 days) and 182 days (95% CI: 146-218 days), both significantly lower than for RT cases with 347 days (95% CI: 240-454 days) and 447 days (95% CI: 222-672 days), (P = 0.01, P = 0.019). Surgery as well as RT led to a fast relief of symptoms. PFI and survival of surgical patients were significantly inferior to that of a comparable patient group treated with conformal hypofractionated RT.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  dog; oncology; radiation oncology; small animal; surgical oncology

Mesh:

Year:  2016        PMID: 27278807     DOI: 10.1111/vco.12248

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  7 in total

1.  Complications associated with iliosacral lymphadenectomy in dogs with metastatic apocrine gland anal sac adenocarcinoma.

Authors:  Yael Huerta; Carlos H De Mello Souza; Laura E Selmic; Alysha McGrath; Owen T Skinner; Katelin V Dark; Marine Traverson; William L Snell; Elizabeth A Maxwell; Judith Bertran; Michelle M M Hasiuk
Journal:  Can Vet J       Date:  2022-09       Impact factor: 1.075

2.  Determination of a serum total calcium concentration threshold for accurate prediction of ionized hypercalcemia in dogs with and without hyperphosphatemia.

Authors:  Elizabeth M Groth; Dennis J Chew; Jody P Lulich; Megan Tommet; Aaron K Rendahl; Brian D Husbands; Eva Furrow
Journal:  J Vet Intern Med       Date:  2019-11-06       Impact factor: 3.333

3.  Quantification of Canine Apocrine Gland Anal Sac Adenocarcinoma (AGASACA) Tumor Specimen Shrinkage after Formalin Fixation.

Authors:  Brandan G Wustefeld-Janssens; Arathi Vinayak; Lindsay A Parker; Danielle L Hollenbeck
Journal:  Animals (Basel)       Date:  2022-07-22       Impact factor: 3.231

4.  Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.

Authors:  Clara Martín-Carrasco; Pablo Delgado-Bonet; Beatriz Davinia Tomeo-Martín; Josep Pastor; Claudia de la Riva; Paula Palau-Concejo; Noemí Del Castillo; Javier García-Castro; Ana Judith Perisé-Barrios
Journal:  Vet Sci       Date:  2022-06-28

5.  Reducing margins for abdominopelvic tumours in dogs: Impact on dose-coverage and normal tissue complication probability.

Authors:  Valeria Meier; Chris Staudinger; Stephan Radonic; Jürgen Besserer; Uwe Schneider; Linda Walsh; Carla Rohrer Bley
Journal:  Vet Comp Oncol       Date:  2021-01-06       Impact factor: 2.613

Review 6.  Animal Models of Cancer-Associated Hypercalcemia.

Authors:  Nicole A Kohart; Said M Elshafae; Justin T Breitbach; Thomas J Rosol
Journal:  Vet Sci       Date:  2017-04-13

7.  Complete Resolution of a Recurrent Canine Anal Sac Squamous Cell Carcinoma with Palliative Radiotherapy and Carboplatin Chemotherapy.

Authors:  Antonio Giuliano; Jane Dobson; Sarah Mason
Journal:  Vet Sci       Date:  2017-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.